- Home
- BQ vs VINC Comparison
BQ vs VINC Comparison
Compare BQ & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- VINC
- Stock Information
- Founded
- BQ 2008
- VINC 2019
- Country
- BQ China
- VINC United States
- Employees
- BQ N/A
- VINC N/A
- Industry
- BQ Other Specialty Stores
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- VINC Health Care
- Exchange
- BQ Nasdaq
- VINC Nasdaq
- Market Cap
- BQ 5.7M
- VINC 6.2M
- IPO Year
- BQ 2020
- VINC N/A
- Fundamental
- Price
- BQ $0.32
- VINC $0.19
- Analyst Decision
- BQ
- VINC Buy
- Analyst Count
- BQ 0
- VINC 2
- Target Price
- BQ N/A
- VINC $2.00
- AVG Volume (30 Days)
- BQ 198.4K
- VINC 564.7K
- Earning Date
- BQ 12-31-2024
- VINC 11-12-2024
- Dividend Yield
- BQ N/A
- VINC N/A
- EPS Growth
- BQ N/A
- VINC N/A
- EPS
- BQ N/A
- VINC N/A
- Revenue
- BQ $98,241,396.00
- VINC N/A
- Revenue This Year
- BQ N/A
- VINC N/A
- Revenue Next Year
- BQ N/A
- VINC N/A
- P/E Ratio
- BQ N/A
- VINC N/A
- Revenue Growth
- BQ N/A
- VINC N/A
- 52 Week Low
- BQ $0.22
- VINC $0.18
- 52 Week High
- BQ $0.74
- VINC $9.37
- Technical
- Relative Strength Index (RSI)
- BQ 33.12
- VINC 28.60
- Support Level
- BQ $0.32
- VINC $0.19
- Resistance Level
- BQ $0.38
- VINC $0.23
- Average True Range (ATR)
- BQ 0.03
- VINC 0.03
- MACD
- BQ -0.01
- VINC 0.00
- Stochastic Oscillator
- BQ 4.48
- VINC 9.21
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.